Carcinogenesis Advance Access published online on February 24, 2005
Carcinogenesis, doi:10.1093/carcin/bgi057
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Etiology and Carcinogenesis, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
* To whom correspondence should be addressed. Matrix metalloproteinase-2 (MMP-2) plays important roles in cancer initiation and progression. Our previous studies revealed that the -1306C>T and -735C>T polymorphisms in MMP2 promoter significantly influence transcriptional activity and their genotypes and haplotypes are associated with susceptibility to several cancers. This case-control study examined the contribution of these two polymorphisms to risk of developing lung cancer. MMP2 genotypes and haplotypes were determined in 770 cases and 777 controls and the associations with risk of lung cancer were estimated by logistic regression. We observed 2-fold [odds ratio (OR), 2.12; 95% confidence interval (CI), 1.64-2.72] or 1.6-fold (OR, 1.57; 95% CI, 1.27-1.95) excess risk of developing lung cancer for the -1306CC or -735CC genotype carriers compared with non-carriers, respectively. A greater risk of lung cancer was associated with the C-1306-C-735 haplotype (OR, 5.01; 95% CI, 2.57-9.78) compared with the T-1306-T-735 haplotype, suggesting a synergic effect of these two polymorphisms. Furthermore, a greater than additive joint effect of the polymorphisms and smoking increased even higher risk of lung cancer. The OR for smokers with the C-1306-C-735 haplotype was 6.24 (95% CI, 4.51-8.64) that was significantly higher than that (OR, 4.10; 95% CI, 2.89-5.81) for smokers with the T-1306- or T-735-containing haplotypes (P <0.001). These results are consistent with our previous findings and further support the hypothesis that gain-of-function of MMP2 resulting from genetic polymorphisms plays an important role in human carcinogenesis.
Received November 30, 2004
Revised January 24, 2005
Accepted February 16, 2005
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION
Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility
2 Department of Thoracic Surgery, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Dongxin Lin, E-mail: dlin{at}public.bta.net.cn
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Sun, Y. Gao, W. Tan, S. Ma, X. Zhang, Y. Wang, Q. Zhang, Y. Guo, D. Zhao, C. Zeng, et al. Haplotypes in Matrix Metalloproteinase Gene Cluster on Chromosome 11q22 Contribute to the Risk of Lung Cancer Development and Progression Clin. Cancer Res., December 1, 2006; 12(23): 7009 - 7017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-A. Yoon, B. Hwangbo, I.-J. Kim, S. Park, H. S. Kim, H. J. Kee, J. E. Lee, Y. K. Jang, J.-G. Park, and J. S. Lee Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer Carcinogenesis, November 1, 2006; 27(11): 2217 - 2222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Heist, A. L. Marshall, G. Liu, W. Zhou, L. Su, D. Neuberg, T. J. Lynch, J. Wain, and D. C. Christiani Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin. Cancer Res., September 15, 2006; 12(18): 5448 - 5453. [Abstract] [Full Text] [PDF]
|
|